• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。
Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.
2
Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.N6-甲基腺苷修饰在卵巢癌中作用的研究进展。
Cancer Control. 2024 Jan-Dec;31:10732748241256819. doi: 10.1177/10732748241256819.
3
Upregulation of miRNA-450b-5p targets ACTB to affect drug resistance and prognosis of ovarian cancer via the PI3K/Akt signaling pathway.miRNA-450b-5p的上调通过PI3K/Akt信号通路靶向β-肌动蛋白,影响卵巢癌的耐药性和预后。
Transl Cancer Res. 2024 Sep 30;13(9):4800-4812. doi: 10.21037/tcr-24-292. Epub 2024 Sep 27.
4
The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.表观遗传修饰在卵巢癌中的新兴作用和治疗意义。
Front Endocrinol (Lausanne). 2022 May 10;13:863541. doi: 10.3389/fendo.2022.863541. eCollection 2022.
5
Ovarian cancer: epigenetics, drug resistance, and progression.卵巢癌:表观遗传学、耐药性与进展
Cancer Cell Int. 2021 Aug 17;21(1):434. doi: 10.1186/s12935-021-02136-y.
6
Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.miR-195-5p 的过表达通过抑制 PSAT1 依赖性 GSK3β/β-catenin 信号通路降低卵巢癌细胞顺铂耐药性和血管生成。
J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1.
7
Regulation of Metastasis by microRNAs in Ovarian Cancer.微小RNA对卵巢癌转移的调控
Front Oncol. 2014 Jun 10;4:143. doi: 10.3389/fonc.2014.00143. eCollection 2014.
8
miR-34 as a Critical Regulator in Ovarian Cancer.miR-34作为卵巢癌的关键调节因子
Curr Mol Med. 2025 Jan 3. doi: 10.2174/0115665240345216241120093846.
9
Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.揭示与奥拉帕利耐药和卵巢癌细胞 PEO1-OR 再敏化相关的 miRNA-mRNA 调控网络,该通路抑制剂为 ATR/CHK1 通路抑制剂。
Cells. 2024 May 17;13(10):867. doi: 10.3390/cells13100867.
10
A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.通过人工智能方法检测卵巢癌复发的诊断 miRNA 面板。
J Cancer Res Clin Oncol. 2023 Jan;149(1):325-341. doi: 10.1007/s00432-022-04468-2. Epub 2022 Nov 15.

引用本文的文献

1
Identification of prognostic subtypes and the role of FXYD6 in ovarian cancer through multi-omics clustering.通过多组学聚类鉴定卵巢癌的预后亚型及FXYD6的作用
Front Immunol. 2025 Mar 18;16:1556715. doi: 10.3389/fimmu.2025.1556715. eCollection 2025.

本文引用的文献

1
MicroRNA miR-378-3p is a novel regulator of endothelial autophagy and function.微小RNA miR-378-3p是内皮细胞自噬和功能的新型调节因子。
J Mol Cell Cardiol Plus. 2022 Dec 8;3:100027. doi: 10.1016/j.jmccpl.2022.100027. eCollection 2023 Mar.
2
Long Non-coding RNA FOXD2-AS1 Silencing Inhibits Malignant Behaviors of Ovarian Cancer Cells Via miR-324-3p/SOX4 Signaling Axis.长链非编码RNA FOXD2-AS1沉默通过miR-324-3p/SOX4信号轴抑制卵巢癌细胞的恶性行为。
Reprod Sci. 2025 Apr;32(4):1003-1012. doi: 10.1007/s43032-024-01719-0. Epub 2024 Oct 25.
3
Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7.卵巢癌细胞来源的外泌体 miR-4516 通过抑制 GAS7 增强卵巢癌细胞对顺铂的耐受性。
Gene. 2024 Nov 15;927:148738. doi: 10.1016/j.gene.2024.148738. Epub 2024 Jun 30.
4
YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.YBX1 通过识别 m5C 修饰促进同源重组和对铂诱导应激的抵抗在卵巢癌中。
Cancer Lett. 2024 Aug 10;597:217064. doi: 10.1016/j.canlet.2024.217064. Epub 2024 Jun 14.
5
CircUBE2D2 regulates HMGB1 through miR-885-5p to promote ovarian cancer malignancy.环状 RNA 结合蛋白 2D2 通过 miR-885-5p 调控 HMGB1 促进卵巢癌细胞恶性表型。
Clinics (Sao Paulo). 2024 Jun 6;79:100391. doi: 10.1016/j.clinsp.2024.100391. eCollection 2024.
6
M2 macrophage-derived exosomal circTMCO3 acts through miR-515-5p and ITGA8 to enhance malignancy in ovarian cancer.M2 巨噬细胞来源的细胞外体 circTMCO3 通过 miR-515-5p 和 ITGA8 发挥作用,增强卵巢癌的恶性程度。
Commun Biol. 2024 May 16;7(1):583. doi: 10.1038/s42003-024-06095-8.
7
M6A-mediated hsa_circ_0061179 inhibits DNA damage in ovarian cancer cells via miR-143-3p/TIMELESS.M6A 介导的 hsa_circ_0061179 通过 miR-143-3p/TIMELESS 抑制卵巢癌细胞中的 DNA 损伤。
Mol Carcinog. 2024 Aug;63(8):1542-1558. doi: 10.1002/mc.23744. Epub 2024 May 15.
8
miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.外周血单个核细胞中miR-3653-3p的表达:揭示卵巢癌的诊断潜力
Biochem Genet. 2024 May 5. doi: 10.1007/s10528-024-10819-0.
9
The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis.miR-1181 和 miR-4314 作为上皮性卵巢癌血清 microRNA 标志物的评估及其对诊断和预后的意义。
Mol Biol Rep. 2024 Apr 15;51(1):515. doi: 10.1007/s11033-024-09464-y.
10
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.在 BRCA 野生型铂耐药复发性高级别浆液性卵巢癌中使用 CHK1 抑制剂 prexasertib:一项 2 期试验。
Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6.

卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。

Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.

作者信息

Dey Bhowmik Arpan, Shaw Pallab, Gopinatha Pillai Mohan Shankar, Rao Geeta, Dwivedi Shailendra Kumar Dhar

机构信息

Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

出版信息

Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.

DOI:10.1016/j.canlet.2024.217357
PMID:39615646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12119979/
Abstract

Ovarian cancer (OC) accounts for the highest mortality rates among all gynecologic malignancies. The high mortality of OC is often associated with delayed detection, prolonged latency, enhanced metastatic potential, acquired drug resistance, and frequent recurrence. This review comprehensively explores key aspects of OC, including cancer diagnosis, mechanisms of disease resistance, and the pivotal role of epigenetic regulation, particularly by microRNAs (miRs) in cancer progression. We highlight the intricate regulatory mechanisms governing miR expression within the context of OC and the current status of epigenetic advancement in the therapeutic development and clinical trial progression. Through network analysis we elucidate the regulatory interactions between dysregulated miRs in OC and their targets which are involved in different signaling pathways. By exploring these interconnected facets and critical analysis, we endeavor to provide a nuanced understanding of the molecular dynamics underlying OC, its detection and shedding light on potential avenues for miRs and epigenetics-based therapeutic intervention and management strategies.

摘要

卵巢癌(OC)在所有妇科恶性肿瘤中死亡率最高。OC的高死亡率通常与检测延迟、潜伏期延长、转移潜能增强、获得性耐药和频繁复发有关。本综述全面探讨了OC的关键方面,包括癌症诊断、疾病耐药机制以及表观遗传调控的关键作用,特别是微小RNA(miR)在癌症进展中的作用。我们强调了在OC背景下控制miR表达的复杂调控机制以及表观遗传学在治疗开发和临床试验进展中的现状。通过网络分析,我们阐明了OC中失调的miR与其参与不同信号通路的靶标之间的调控相互作用。通过探索这些相互关联的方面并进行批判性分析,我们努力对OC潜在的分子动力学、其检测提供细致入微的理解,并为基于miR和表观遗传学的治疗干预及管理策略的潜在途径提供线索。